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Abstract
Background: Multiple types of assays allow sensitive detection of virus-specific neutralizing antibodies. For
example, the extent of antibody neutralization of HIV-1, SIV and SHIV can be measured in the TZM-bl cell line
through the degree of luciferase reporter gene expression after infection. In the past, neutralization curves and
titers for this standard assay have been calculated using an Excel macro. Updating all instances of such a macro
with new techniques can be unwieldy and introduce non-uniformity across multi-lab teams. Using Excel also poses
challenges in centrally storing, sharing and associating raw data files and results.
Results: We present LabKey Server’s NAb tool for organizing, analyzing and securely sharing data, files and results
for neutralizing antibody (NAb) assays, including the luciferase-based TZM-bl NAb assay. The customizable tool
supports high-throughput experiments and includes a graphical plate template designer, allowing researchers to
quickly adapt calculations to new plate layouts. The tool calculates the percent neutralization for each serum
dilution based on luminescence measurements, fits a range of neutralization curves to titration results and uses
these curves to estimate the neutralizing antibody titers for benchmark dilutions. Results, curve visualizations and
raw data files are stored in a database and shared through a secure, web-based interface. NAb results can be
integrated with other data sources based on sample identifiers. It is simple to make results public after publication
by updating folder security settings.
Conclusions: Standardized tools for analyzing, archiving and sharing assay results can improve the reproducibility,
comparability and reliability of results obtained across many labs. LabKey Server and its NAb tool are freely
available as open source software at http://www.labkey.com under the Apache 2.0 license. Many members of the
HIV research community can also access the LabKey Server NAb tool without installing the software by using the
Atlas Science Portal (https://atlas.scharp.org). Atlas is an installation of LabKey Server.
Background
Standardized techniques for measuring neutralizing anti-
body (NAb) response to infectious agents are important
tools for studies that address pathogenesis and vaccine
development. Without proper standardization, variability
in techniques can obscure differences in the quality and
quantity of antibody responses. Luciferase-based repor-
ter gene assays have been developed to assess the activ-
ity of a range of neutralizing antibodies [1-5]. For
example, the TZM-bl NAb assay for HIV-1, SIV and
SHIV provides a standard method for measuring neutra-
lization and identifying promising antibodies for the
development of HIV vaccines and immunotherapeutics
[1]. This assay has been widely adopted by collaborating
labs throughout the HIV research community [6-9]
because it is sensitive, quantitative, high-throughput,
reproducible, accurate, swift, and validated for good
clinical lab practices (GCLP)[1,7].
Figure 1 diagrams how the TZM-bl cell line is used to
measure the success of antibodies in neutralizing HIV in
the TZM-bl assay. The TZM-bl (JC53-bl) cell line has
been genetically altered to express HIV entry receptors
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(CD4, CXCR4 and CCR5) and contain Tat-inducible
luciferase (Luc) and b-galactosidase reporter genes. In
the TZM-bl assay, virus and antibodies are incubated
together at a range of concentrations, then combined
with TZM-bl cells vulnerable to infection. After a
further two days of incubation, measurement of relative
luminescence units (RLU) compared to controls indi-
cates the success of neutralization. Greater success in
neutralization produces lower infection and thus lower
luminescence. The concentration of antibodies necessary
to noticeably reduce infection (e.g., to achieve 50% neu-
tralization) is used as a measure of the efficacy of the
antibody. Measurement of luminescence usually takes
place on one or many multi-well plates. Plates include
virus control and cell control groups, plus replicates for
each dilution. The luminometer outputs raw data in a
standardized format directly into an Excel spreadsheet.
In the past, an Excel macro has been used to analyze
these spreadsheets and calculate neutralization curves.
The macro must be installed manually on every compu-
ter where researchers wish to use it. If updates to calcu-
lation procedures or plate layout patterns are needed,
they must be applied on every computer where the
macro is used. Result and source files must be painstak-
ingly named to allow association of raw data and com-
pleted analyses. Files can quickly proliferate on multiple,
distributed computers unless careful centralization,
archiving and sharing procedures are in place and duti-
fully followed.
We present a standardized software tool and data
management system for neutralizing antibody assays
that can enhance the reproducibility, reliability, compar-
ability and retention of results for assays such as TZM-
bl. The tool makes it easy to apply standardized calcula-
tions through a web-based interface; centrally archive
both data and results; and securely share this informa-
tion between collaborating labs and beyond. Updates to
the tool can be made once to the central server and
appear uniformly to all users. A graphical plate designer
makes it easy to design customized plate templates for
new, high-throughput experiments and make them
available to all users of the central server.
Implementation
Architecture
LabKey Server [10,11] is a web application implemented
in Java. It runs on the Apache Tomcat web server and
stores its data in a relational database, either Post-
greSQL or Microsoft SQL Server. LabKey Server has
been tested on computers running Microsoft Windows
and most Unix variants, including Linux, Macintosh
OSX and Solaris.
Incubate virus         with 
neutralizing antibodies
Add TZM-bl cells





No infection, no light
Infection produces light
Figure 1 Diagram of neutralization assay steps. A virus is incubated for an hour with neutralizing antibodies, then TZM-bl cells are added
and the mixture is incubated for an additional two days. The TZM-bl cells have been genetically modified with Tat-inducible luciferease, so they
will luminesce when infected. The extent of infection is measured by observing the luminescence of these cells. High levels of luminescence
indicate high levels of infection, so antibodies have not had success in neutralizing the virus, leaving it free to infect cells.
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LabKey Server’s NAb tool is packaged in a Java-based
module that encapsulates user interface elements and
calculation logic for designing, processing and displaying
structured assays of various kinds.
Details of LabKey Server’s architecture and assay mod-
ule have been covered elsewhere [10]. LabKey Server
v11.1, available in April 2011, is the 20th official, public
release of the platform since 2005.
Results
Overview of NAb tool
Users are prompted to provide the NAb tool with a raw
instrument file produced by their luminometer, plus
relevant metadata about the batch, run and samples that
have been processed. Required metadata include charac-
teristics necessary for calculations (e.g., initial dilution,
dilution factor and desired curve fit method). Optional
metadata include characteristics of the experiment that
can be used for tracking purposes (e.g., experiment per-
former, incubation time and virus name). Both raw data
and metadata are analyzed automatically by the system
to estimate the titers at which specified levels of neutra-
lization are seen for each sample/virus combination.
Results can be integrated with other data types (such as
specimen information and clinical data for study partici-
pants). The NAb tool displays neutralization curves,
titers and source data in a secure, interactive, web-based
interface.
Options for leveraging the NAb tool
The LabKey Server NAb tool can be accessed in two
ways:
• By logging into to the Atlas Science Portal. This
option is available to participating member consortia
of the Global HIV Enterprise [10,12,13].
• By installing and configuring a LabKey Server
instance of your own. This option allows you to
administer and customize your own, private LabKey
Server for your lab or consortium.
Detailed information for these options is available in
the “Availability and Requirements” section of this
paper.
Tutorials and documentation
Full documentation and tutorials for setting up, config-
uring and using LabKey Server and its NAb assay are
available at http://www.labkey.org. This documentation
is updated regularly to match the currently released ver-
sion of LabKey Server. The LabKey Server NAb assay
tutorial [14] provides a detailed walk-through and sam-
ple data.
Assay plate options
The tool supports both low-throughput (single-plate)
and high-throughput (multi-plate) NAb assays per-
formed in either a 96-well or 384-well plate format. At
present, a low-throughput assay typically utilizes a 96-
well plate, usually prepared with five specimens in eight
dilutions of two replicates each, as shown in Figure 2. A
high-throughput assay typically uses 384-well plates,
allowing for more samples per run. A high-throughput
run may consist of up to eight plates. High-throughput
samples are diluted across plates; in contrast, low-
throughput samples are diluted within a single plate.
Plate layout may be customized for both low- and high-
throughput assays.
Calculation of results
The NAb tool calculates the percent neutralization for
each dilution or concentration after subtraction of back-
ground activity and fits a curve to the neutralization
profile. It then uses this curve to calculate neutralizing
antibody titers for chosen benchmarks, area-under-the-
curve (AUC) and error estimates. Five-parameter, four-
parameter, polynomial, and point-based methods are all
currently used to calculate curve fits. For each method
of curve fit, the tool calculates up to three inhibitory
dilutions or inhibitory concentrations, according to the
cutoff percentages chosen by the user. For example, the
user might ask the tool to calculate IC20, IC50 and
IC80, the concentrations at which the antibody inhibits
20%, 50% and 80% of infections. The tool also uses the
fitted curve to calculate the AUC, the positive-area-
under-the-curve (PostiveAUC) and curve fit error esti-
mates. AUC is the total area under the curve, with nega-
tive regions counting against positive regions.
PositiveAUC includes only the areas under the curve
that are above the x-axis.
In addition to calculating curve-based neutralization
titers, the tool also calculates “point-based” titers
according to the method of Reed and Muench [15].
This is done by linearly interpolating between the two
replicates on either side of the target neutralization
percentage.
Formal comparisons between five-parameter, four-
parameter, polynomial and point-based methods for cal-
culating titers are not currently available. In general,
five-parameter, four-parameter and polynomial methods
provide more averaging than point-based methods, so
they generate smoother trend lines. Common techniques
for calculating five-parameter, four-parameter and poly-
nomial curve fits are described elsewhere [16,17].
As part of ongoing development of the tool, new cal-
culation techniques (such as a five-parameter curve fit)
have been added to the tool and quickly deployed to all
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users. When desirable, new calculations (such as area-
above-the-curve calculations) have automatically been
added to results views for existing data. This meant that
new insights into analysis techniques could quickly and
transparently be applied to existing data, alongside old
techniques. Automated and manual testing are per-
formed before every public release of LabKey Server to
ensure that analyses performed with new versions of the
software produce results consistent with previous
releases.
Usage scenario for the LabKey Server NAb tool
To use the NAb tool, a scientist typically follows these
steps:
1. Set up an assay folder. After setting up a LabKey
Server, an administrator creates an assay-type folder
with appropriate permissions for user access. The
home page for the folder shown in Figure 2 includes
the Assay Dashboard (the starting place for upload-
ing and processing NAb data) and the File web part
(the general-purpose tool for uploading and import-
ing files and data to the server).
2. Configure a plate template. A user next creates a
plate template to match the design of the assay, or
reuses an existing template. The template maps the
contents of each well, including specimen controls
and replicates. Figure 3 shows the plate template
editor.
3. Create an assay design. With a plate template in
hand, the user next creates an assay design that
includes both this plate template and appropriate
fields, such as “Sample ID” and “Initial Dilution,” as
shown in Figure 4. This design is used as the frame-
work for uploading many individual assay runs.
4. Upload files and import data. After creating an
assay design, a user can begin uploading files to the
repository and simultaneously importing data from
those files into the database. A part of this process,
the assay design guides the collection of appropriate
metadata for the assay run, as shown in Figure 5.
This information is used to determine data proces-
sing and to map samples to plate locations. Informa-
tion collected typically indicates whether the sample
is being diluted or concentrated; the initial dilution
or concentration of each sample; the dilution factor;
1-3 cut-off percentages for calculation of inhibitory
concentrations or dilutions; a unique sample identi-
fier; and the default curve fit method.
5. View results. Curve fits and related results are
calculated automatically for each assay run during
the import process. Figure 6 shows a results view for
a low-throughput NAb assay. Calculated results are
displayed towards the top of the page, while raw
plate data are provided at the bottom. The results
page shows calculations for inhibitory concentration
(or dilutions), areas under the curves and the stan-
dard deviations of controls, both viral and cell. A
drop-down menu allows users to choose which
curve fit mechanism is used to calculate displayed
results.
Data integration and quality control
LabKey Server allows researchers to integrate informa-
tion from NAb assays with other study information
through sample, participant and visit identifiers [10].
The platform also provides mechanisms for performing
quality control before sharing NAb results widely and
integrating these results with other data sources. Figure 7
Figure 2 Assay dashboard. The assay dashboard provides a central location for managing different assays and their associated runs. This
dashboard has been customized to include a list of all assay designs available in the current folder. It also displays a file management interface
for uploading files and importing file data to appropriate assay designs.
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shows a schematic overview of how data can flow into a
LabKey Server from diverse sources, undergo quality
control and become available to a range of data custo-
mers through a web-based portal.
Typically, imported NAb data includes sample identi-
fiers (sample IDs). These are used to look up the partici-
pant IDs and visit IDs associated with the samples
during assay run import. Data are initially stored in a
private folder, along with sample IDs, participant IDs
and visit IDs. Quality control checks are then performed
to identify inconsistencies in the data and users can see
the errors immediately onscreen.
After the data have been reviewed privately for accu-
racy, they are typically then transferred to a shared inte-
gration folder called a study. A study allows groups of
researchers to use participant and visit IDs to integrate
data of many different types, such as specimen informa-
tion, clinical data and other assay results for a study par-
ticipant. Just like NAb data, all of these data types have
first been reviewed for accuracy before they are trans-
ferred to a study folder for sharing and integration.
Additional features of LabKey Server
LabKey Server includes a range of additional built-in
features that can be helpful to users of the NAb tool.
These include a fine-grained security model, auditing, a
robust API and tools for data integration. A full review
of LabKey Server’s features as of v10.3 is available else-
where [10].
The platform’s folder- and role-based security model
allows a single LabKey Server to support multiple
groups privately managing NAb analyses in protected
projects and folders. Data can be shared based on the
role and group memberships of each user. Furthermore,
finished data can be released publicly by simply lowering
the permissions requirements for the particular sub-
folder that contains the data.
LabKey Server’s assay infrastructure supports auditing
and can be used to achieve GCLP. For example,
imported runs can be re-imported to the system as new
runs for error correction, but existing runs cannot be
edited.
NAb data stored on a LabKey Server can be accessed
through LabKey’s rich API. This API supports a variety
of programming languages, including JavaScript and
Perl, which makes it easy for labs to write custom tools
that work with data (including NAb data) stored on a
LabKey Server.
Current Usage
LabKey Server’s NAb tool has been adopted by multiple
consortia within the Global HIV Enterprise [10,12,13] for
uploading, processing and sharing results of the TZM-bl
NAb assay. These labs use the tool as part of the Atlas
Science Portal [18], which is itself an installation of Lab-
Key Server. The NAb tool has been used successfully by
14 labs across 5 organizations within the Enterprise: the
Collaboration for AIDS Vaccine Discovery (CAVD), the
Figure 3 Plate template editor. The LabKey Server plate template editor allows you to indicate which wells contain particular specimens,
replicates and controls. Processing of sample data depends on the layout of each plate, as indicated through a plate template. The plate
template editor’s graphical interface allows you to select a specimen and then drag across the plate template editor to “paint” with the chosen
specimen. This makes it easy to edit large plate templates. A 96-well template is displayed here; a 384-well template is also available.
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Center for HIV Vaccine Immunology (CHAVI), the Vac-
cine Immunology Statistical Center (VISC), the HIV Vac-
cine Trials Network (HVTN) and the U.S. Military HIV
Research Program. As of January 2011, these labs have
used the NAb assay tool to upload and store over 40,000
NAb assay runs. As of May 2010, Atlas supported approxi-
mately 2,800 user accounts originating in roughly 350
organizations and 36 countries [10].
Figure 4 Assay designer. The LabKey Server assay designer [10] provides a pre-prepared assay design for both low- and high-throughput TZM-
bl NAb assays. Both the plate template and the fields for this design can be customized. This figure shows the default design for high-
throughput NAb experiments.
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Post-publication sharing of NAb assay analyses is a
particularly notable aspect of how the LabKey Server
NAb tool is being used. Multiple labs within the CAVD
consortium have made their NAb data and analyses
public on the Atlas portal [18]. This portal provides an
interactive interface that provides sortable and filterable
grid views of results. Figure 6 shows an example of a
NAb assay results view available publicly on Atlas [19].
Figure 5 NAb assay import screen. This image shows how users indicate metadata and cut-off percentages for neutralization titers for a high-
throughput NAb assay.
Figure 6 LabKey Server NAb results view. The calculated results of a NAb run are displayed in the “Run Summary.” This example shows a
low-throughput NAb run that has been shared publicly on the Atlas server as part of a completed CAVD study [19].
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Results from other CAVD studies can be explored using
the CAVD study design browser [20].
Discussion
Overview of advantages
Robust software tools can make it easier for assay techni-
ques to be standardized and transferred uniformly to
multiple labs, as long as they can be updated swiftly and
consistently to reflect new techniques. Server-based tools
like the LabKey Server NAb tool can be delivered as soft-
ware-as-a-service (SaaS) and deployed and updated uni-
formly, unlike Excel-based macros. Advantages of the
LabKey Server NAb tool extend beyond uniform deploy-
ment. The NAb tool also provides configurable support
for evolving workflows and high-throughput techniques.
Furthermore, it provides a secure, web-based platform
for archiving, integrating and sharing data and files, fea-
tures unavailable with Excel alone.
Software-as-a-service
Updates to the LabKey Server NAb tool (such as the addi-
tion of a new curve fit algorithm) can be made efficiently
and transparently on a central web server. Unlike a macro,
updates do not need to be installed on a multiplicity of
machines. This eliminates worries about which version of
the macro was used to calculate results; instead, results are
displayed centrally using the latest version of the tool and
algorithms. At the same time, upgrading the LabKey Ser-
ver NAb tool does not overwrite results calculated at the
time of data import; these original results are retained in
particular views. Optionally, new algorithms (such as a
new calculation of “area under the neutralization curve”)
can be applied automatically to all archived data. This
makes it swift and easy to augment old analyses with data
from new techniques.
Template customization
The flexibility of LabKey Server’s NAb tool makes it
easier to customize and refine than an Excel macro.
LabKey Server’s assay framework provides a graphical
plate template designer that makes it easy to adjust the
data formats understood by the NAb tool and share
new templates with other users. Easy template customi-
zation is particularly helpful when using swiftly-evolving,
high-throughput techniques.
A central data repository
Data and results that live in a central, secure repository
(such as a LabKey Server) are not lost when a techni-










labid uspeci txtpid parusp drawdm drawdd drawdy
262 4633 9.99E+08 4632 3 23 2005
308 13472 9.99E+08 13471 3 23 2005
262 4641 9.99E+08 4640 4 14 2005
262 4650 9.99E+08 4649 5 9 2005
262 4652 9.99E+08 4651 5 11 2005
308 13480 9.99E+08 13479 5 11 2005
262 4668 9.99E+08 4667 4 13 2005
308 13486 9.99E+08 13485 4 13 2005
262 4684 9.99E+08 4683 5 11 2005
262 4751 9.99E+08 4750 6 21 2005
308 13560 9.99E+08 13559 6 21 2005
262 4769 9.99E+08 4768 6 28 2005
308 13578 9.99E+08 13577 6 28 2005
262 4850 9.99E+08 4849 6 1 2005
262 4897 9.99E+08 4896 8 17 2005
262 4898 9.99E+08 4896 8 17 2005
262 4914 9.99E+08 4913 8 30 2005
308 13933 9.99E+08 13932 8 30 2005
262 4922 9.99E+08 4921 9 1 2005
308 13941 9.99E+08 13940 9 1 2005
262 4934 9.99E+08 4933 9 14 2005
308 13953 9.99E+08 13952 9 14 2005
262 4935 9.99E+08 4933 9 14 2005
308 13954 9.99E+08 13952 9 14 2005
262 4950 9.99E+08 4949 9 28 2005
308 13969 9.99E+08 13968 9 28 2005
262 4951 9.99E+08 4949 9 28 2005
308 13970 9.99E+08 13968 9 28 2005
307 773 9.99E+08 772 8 24 2005
307 774 9.99E+08 772 8 24 2005
307 800 9.99E+08 799 8 30 2005













Figure 7 LabKey Server data flows. This figure shows how data flows into a LabKey Server in many forms (e.g., Excel, text and DataFax case
report forms) from many sources (e.g., labs, clinics and repositories). Once within the system, data can be accessed by collaborators (e.g., labs,
principal investigators and statisticians) in desired formats (e.g., data grids, custom R views or charts) through a web-based portal.
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when a single computer is lost. LabKey Server’s granular
permissions framework makes it easy for collaborating
researchers to pool data in a secure environment, or to
share subsets of data publicly after publication.
Usage for other assays
The LabKey Server NAb tool described here can be
used for other 96-well and 384-well plate-based assays
beyond the TZM-bl NAb assay. These might include
assays that utilize optical density, luminescence, fluores-
cence, radio activity and other quantitative measures as
end points. Moreover, the tool is not limited to assays
for NAbs. Using an existing, refined tool like LabKey
Server can help researchers standardize on a common
platform for many assays across many studies and labs.
Furthermore, researchers can avoid writing new, custom
macros for similar assays.
There are several constraints to applying this tool to
other assays. To use the existing tool for other assays,
experiments must conform to specific plate layouts that
can be described with the tool. Furthermore, analyses of
such assays must conform to the patterns supported by
the tool.
As mentioned previously, code modifications to the
tool itself can also be made to support additional, cus-
tom needs of such assays. The degree of difficulty of
these modifications depends on their scope.
Future Directions
As high-throughput NAb assays evolve, the LabKey
team will continue to customize the NAb tool to new
needs. There is interest in extending the tool to support
multi-virus experiments. Today, the tool assumes that
each plate contains a single virus control. Future work
would generalize the tool further to analyze plates that
contain multiple virus controls.
Beyond the NAb tool, the LabKey team will continue
to develop new, built-in assays for the platform. LabKey
Server’s assay framework and robust API has also been
used by third-party developers to produce new assay
modules in languages such as JavaScript [10]. LabKey
Software provides ongoing support and development of
the LabKey Server platform.
Conclusions
The LabKey Server NAb tool provides a standardized
tool for calculating, storing and sharing data from low-
and high-throughput NAb experiments. These experi-
ments are essential for identifying subtle differences in
antibody success in neutralization of HIV-1, SIV and
SHIV and ultimately for developing novel vaccines and
treatments for AIDs. The LabKey Server NAb tool pro-
vides a wide range of advantages over the Excel macro
that has been used in the past for analyzing TZM-bl
NAb assay data. These advantages include standardized
deployment across labs, swift customizability and a web-
based interface for organizing, integrating, archiving and
sharing data and files.
Scalable, robust tools for analyzing and managing
experimental results in a standardized manner will only
become more valuable as distributed teams of research-
ers use high-throughput techniques to produce ever-
increasing volumes of data. The open source license for
LabKey Server and its NAb tool allow other researchers
to freely leverage, customize and improve this tool.
Availability and Requirements
LabKey Server Open Source and Compiled Binaries
The LabKey Server open source software is freely avail-
able for download at http://www.labkey.org under the
terms of the Apache License 2.0 [21]. This site also pro-
vides documentation, tutorials and demos for users and
developers, plus instructions for developers who wish to
contribute code to the project through the LabKey Sub-
version repository.
Compiled binaries for Windows, Unix, Linux or Macin-
tosh installation are available for free through LabKey
Software at http://www.labkey.com. A graphical installer
is available for computers running Windows XP or later.
It includes the LabKey Server web application; the
Apache Tomcat web server, v5.5.29; the Java Runtime
Environment, v1.6.0-22; the PostgreSQL database server,
v8.3.7; and additional third-party components.
• Project name: LabKey Server
• Project home page: http://www.labkey.org
• Operating system(s): Platform independent
• Programming languages: Java, JavaScript, R, Perl,
SAS, etc.
• Other requirements, as of LabKey v11.1: Apache
Tomcat (5.5.29, 5.5.31 or 5.5.32); Java Runtime
Environment 6; and either PostgreSQL (8.2, 8.3 or
9.0) or Microsoft SQL Server (2005, 2008 or 2008
R2). Check the project site for latest requirements of
the most recent release.
• License: Apache License 2.0 [21]
Access to the Atlas Science Portal
Access to Atlas is available to participating members of
the research networks as part of the Global HIV Enter-
prise. To inquire about access, contact atlas@scharp.org.
Published NAb results are available to the public with-
out logon at https://atlas.scharp.org. At present, many
NAb results can be found in completed CAVD studies,
which are located on Atlas in the VISC folder.
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